



**World Health  
Organization**

**Department of Immunization,  
Vaccines and Biologicals (IVB)**

# **SAGE**

## **meeting**

**Strategic Advisory Group of Experts  
on Immunization  
31 March - 02 April 2020**

**Virtual meeting, WHO  
Geneva, Switzerland**

This document can be found online after the meeting at the following link:

<https://www.who.int/immunization/sage/meetings/2020/april/en/>

This interactive pdf contains all background documents for the corresponding meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization.

To function correctly, this document should be opened with [Acrobat Reader](#) (please download if necessary).

Navigation is done via the interactive table of content page. Each session landing page contains links to the executive summary and all background documents (tagged as either essential or additional). All session documents open as new tabs in the Adobe reader (pdf attachments).

Tip: Avoid opening more than 6-8 tabs at a time to preserve navigability.

Notes:

(1) This document functions only in a limited mode on hand-held devices. See “How to Guide”.

(2) Presentations from the meeting will be made available once the meeting has concluded at the above link and through an additional interactive PDF.

## TABLE OF CONTENTS

<b>AGENDA</b>	
<b>SAGE ADMINISTRATION AND GENERAL DOCUMENTS</b>	
A	Terms of reference
B	SAGE members
C	Declaration of interests for WHO experts
D	SAGE tracking sheet
E	Current SAGE working groups
F	Provisional list of meeting participants
G	“How to” guide for interactive SAGE yellow book
<b>SESSIONS (with access to background materials)</b>	
1	Report from Director, IVB and Regional Updates
2	Measles outbreak epidemiology and WHO coordination
3	Update on SARS-CoV2 vaccine development
4	Update on Ebola
5	Polio
6	IA2030 monitoring and evaluation framework
7	Global Vaccine Safety Blueprint 2.0



Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization  
 31 March – 01 April 2020  
 Virtual Meeting  
 Draft agenda

Tuesday, 31 March 2020

Time	Session	Purpose of session, target outcomes and questions for SAGE	Duration
10:00	<b>Closed SAGE meeting</b>	Preparation of the sessions of the day. Other important discussion items.	1h
11:00	<b>Welcome – introduction of participants</b>  A. CRAVIOTO. Chair of SAGE.		10 min.
11:10	<a href="#"><u>Global and Regional Reports - Session 1</u></a>  Report from the Director of IVB. K. O'BRIEN. WHO. 20 min.  Updates from the Regions. 20 min.  Update from Gavi. 10 min.  Discussion: 40 min.	<b>FOR INFORMATION</b>	1h 30 min.
<b>12:40</b>	<b>Break</b>	<b>Break</b>	<b>15 min.</b>
12:55	<a href="#"><u>Measles outbreak epidemiology and WHO coordination - Session 2</u></a>  Response to measles outbreaks. 25 min. K. KRETSINGER  Ongoing and upcoming measles and rubella policy and strategic work. 10 min. K. O'BRIEN  Discussion: 25 min.	<b>FOR DISCUSSION</b>  Target outcomes: 1. SAGE is informed of the current status of measles outbreaks and WHO response efforts.  2. SAGE provides feedback on current WHO plan for upcoming measles rubella strategic work and addressing policy needs.	1h
<b>13:55</b>	<b>Break</b>	<b>Break</b>	<b>30 min.</b>
14:25	<a href="#"><u>Update on SARS-CoV2 vaccine development- Session 3</u></a>	<b>FOR INFORMATION</b>	1h
<b>15:25</b>	<b>Break</b>	<b>Break</b>	<b>15 min.</b>
15:40	<a href="#"><u>Update on Ebola - Session 4</u></a>	<b>FOR INFORMATION</b>  Update on the Ebola epidemic in DRC, on vaccine use and safety reports, and other vaccine developments.	30 min.
<b>16:10</b>	<b>End of Day</b>		



Wednesday, 01 April 2020

10:00	<b>Closed SAGE meeting</b>	Preparation of the sessions of the day. Recap of day 1. Other important discussion items.	1h
11:00	<b><a href="#">Polio - Session 5</a></b>	<b>FOR DISCUSSION AND DECISION</b>	2h 30 min.
	<p>Update from the Global Polio Eradication Initiative. M. ZAFFRAN. WHO. 15 min.</p> <p>Questions: 5min.</p> <p>Update on cVDPV2 epidemiology and overview of the new cVDPV2 outbreak response strategy focusing on tOPV and IPV use. O. MACH. WHO. 15 min.</p> <p>Questions: 5 min.</p> <p>Update on nOPV2 development: <ul style="list-style-type: none"> <li>• Summary of nOPV2 clinical data. A. BANDYOPADHYAY. BMGF. 15 min.</li> <li>• Framework for initial-use of nOPV2 under Emergency Use Listing (EUL). G. MACKLIN. WHO. 15 min.</li> </ul> </p> <p>Discussion: 30 min.</p> <p>Report from SAGE Polio Working Group including recommendations for regions considering switch to IPV only schedules. I. JANI. SAGE Member. 20 min.</p> <p>Discussion: 30 min.</p>	<p>SAGE will be informed on the current status of the polio eradication program; revised strategies to respond to cVDPV outbreaks; and nOPV2 development.</p> <p>SAGE will be asked to review and consider for endorsement:</p> <ul style="list-style-type: none"> <li>• Policy implications of the new cVDPV2 outbreak response strategy (tOPV and IPV use)</li> <li>• Framework for initial use of nOPV2.</li> </ul>	
13:30	<b>Break</b>	<b>Break</b>	<b>30 min.</b>
14:00	<b><a href="#">IA2030 Monitoring and Evaluation framework - Session 6</a></b>	<b>FOR DISCUSSION</b>	1h
	<p>Presentation on the aims and principles of IA2030 Monitoring, Evaluation &amp; Action (ME&amp;A) Framework, its development process and the Strategic Priority Goals and Objectives. A. Lindstrand. WHO. 15 min.</p> <p>GVAP lessons learned and implications for the IA 2030 ME&amp;A Framework. N. Arora. SAGE DoV Working Group. 5 min.</p> <p>Possible links of IA2030 ME&amp;A Framework to Governance &amp; Accountability mechanisms. K. O'Brien. WHO. 5 min.</p> <p>Questions to SAGE. A. Lindstrand. WHO. 5 min.</p> <p>Discussion: 30 min.</p>	<p>1. Share updates from the IA2030 M&amp;E Task Force, including:</p> <ul style="list-style-type: none"> <li>• Aims and principles of IA2030 Monitoring, Evaluation &amp; Action (ME&amp;A) Framework</li> <li>• IA2030 ME&amp;A Framework development process</li> <li>• Revised IA2030 Strategic Priority Goals and Objectives</li> <li>• Possible links of IA2030 ME&amp;A Framework to Governance &amp; Accountability mechanisms</li> <li>• How GVAP lessons learned inform development of the IA 2030 ME&amp;A Framework</li> </ul> <p>2. Receive feedback from SAGE on:</p> <ul style="list-style-type: none"> <li>• IA2030 ME&amp;A Framework development process</li> <li>• Options for development of IA2030 ME&amp;A Framework indicators and targets</li> <li>• Possible links of IA2030 ME&amp;A Framework to Governance &amp; Accountability mechanisms</li> </ul>	
15:00	<b>Break</b>	<b>Break</b>	<b>15 min.</b>

15:15	<a href="#">Global Vaccine Safety Blueprint 2.0 - Session 7</a>	<b>FOR DISCUSSION AND DECISION</b>	1h
	<p>Introduction. K. JOHANSEN. SAGE member. 5 min.</p> <p>Global Vaccine Safety Blueprint 2.0. E. Asturias-D. Salmon. (TBC). 15 min.</p> <p>Discussion: 40 min.</p>	<p>For revision and endorsement of the Global Vaccine Safety Blueprint 2.0</p> <p>Questions to SAGE proposed by GACVS:</p> <ol style="list-style-type: none"> <li>1. What strategic shift could be made to move from GVS1.0 to GVS2.0?</li> <li>2. Are there strategies for identifying resources and mechanisms for finding funds without using those reserved for vaccination?</li> <li>3. What are the recommendations for moving forward, including possible adjustments to the Global Vaccine Safety Initiative?</li> </ol>	

**16:15 End of the day**

**Thursday, 02 April 2020**

12:00	<b>Closed SAGE meeting</b>	Recap of day 2. Other important discussion items.	2h
-------	----------------------------	---	----

**14:00 End of the meeting**

## SESSION 1: GLOBAL AND REGIONAL REPORTS

EXECUTIVE SUMMARY	
-	Not applicable

BACKGROUND DOCUMENTS	
1.1	SAGE meeting report, October 2019
1.2	AFRO RITAG meeting report, November 2019
1.3	EURO RITAG (ETAGE) meeting report, October 2019
1.4	Global Advisory Committee on Vaccine Safety (GACVS) meeting report, December 2019
1.5	Immunization and Vaccine-related Implementation Research Advisory Committee Executive summary, September 2019

## SESSION 2: MEASLES OUTBREAK EPIDEMIOLOGY AND WHO COORDINATION

EXECUTIVE SUMMARY	
2.0	Executive Summary: Measles & Rubella session

BACKGROUND DOCUMENTS (essential)	
-	None

BACKGROUND DOCUMENTS (additional)	
2.1	WHO Strategic and Technical Advisory Group for Infectious Hazards (STAG-IH) report of the 4th face-to-face meeting, 3–4 December 2019, Geneva, Switzerland

## SESSION 3: UPDATE ON SARS-COV2 VACCINE DEVELOPMENT

EXECUTIVE SUMMARY	
3.0	Executive Summary: Update on SARS-Cov2 Vaccine Development

BACKGROUND DOCUMENTS (essential)	
-	None

BACKGROUND DOCUMENTS (additional)	
3.1	2019 novel Coronavirus Global research and innovation forum: towards a research roadmap (Report from the 11-12 February 2020 Global Forum on research and innovation for COVID-19)
3.2	Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19), 16-24 February 2020
3.3	Coronavirus disease 2019 (COVID-19) Situation Report – 51 (11 March 2020)
3.4	DRAFT landscape of COVID-19 candidate vaccines, 4 March 2020

## SESSION 4: UPDATE ON EBOLA

EXECUTIVE SUMMARY	
4.0	Executive Summary: Update on Ebola

BACKGROUND DOCUMENTS (essential)	
-	None

BACKGROUND DOCUMENTS (additional)	
4.1	Ebola virus disease, Democratic Republic of the Congo, External Situation Report 83, 10 March 2020
4.2	WHO recommended criteria for declaring the end of the Ebola virus disease outbreak, updated 4 March 2020

## SESSION 5: POLIO

EXECUTIVE SUMMARY	
5.0	Executive Summary: Polio session

BACKGROUND DOCUMENTS (essential)	
5.1	SAGE Polio WG report on summary of the deliberations of the SAGE Working Group meeting 11-12 Feb. 2020
5.2	Summary of nOPV2 development and clinical data (This summary will provide information on the clinical data from nOPV2 trials that show its immunogenicity, safety, and genetic stability)
5.3	Framework for nOPV first-use under Emergency Use Listing (EUL) recommendation (This framework provides information on criteria for first nOPV use under EUL)
5.4	Strategy for the Response to Type 2 Circulating Vaccine-Derived Poliovirus 2020–2021
5.5	Consideration for programmatic use: mOPV2 versus tOPV

BACKGROUND DOCUMENTS (additional)	
-	None

## SESSION 6: IA2030 MONITORING AND EVALUATION FRAMEWORK

EXECUTIVE SUMMARY	
6.0	Executive Summary: IA2030 M&E Framework

BACKGROUND DOCUMENTS (essential)	
6.1	Revised IA2030 Strategic Priority Goals and Objectives
6.2	The Global Vaccine Action Plan (GVAP) 2011-2020 Review and Lessons Learned Annex: The GVAP Monitoring, Evaluation and Accountability (M&E/A) Framework
6.3	IA2030 M&E Task Force Terms of Reference



## SESSION 7: GLOBAL VACCINE SAFETY BLUEPRINT 2.0

EXECUTIVE SUMMARY	
7.0	Executive Summary: Global Vaccine Safety Blueprint 2.0

BACKGROUND DOCUMENTS (essential)	
7.1	Global Vaccine Safety Blueprint 2.0 draft 3 incorporating Global Vaccine Safety Summit comments

BACKGROUND DOCUMENTS (additional)	
7.2	Global Vaccine Safety Blueprint 2.0 landscape analysis